Integrin &#x03B1;6 promotes esophageal cancer metastasis and is targeted by miR-92b

Gang Ma; Chao Jing; Furong Huang; Xukun Li; Xiufeng Cao; Zhihua Liu

doi:10.18632/oncotarget.14259

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Integrin α6 promotes esophageal cancer metastasis and is targeted by miR-92b

Gang Ma, Chao Jing, Furong Huang, Xukun Li, Xiufeng Cao _ and Zhihua Liu

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:6681-6690. https://doi.org/10.18632/oncotarget.14259

Metrics: PDF 1707 views | HTML 2353 views | ?

Abstract

Gang Ma1,*, Chao Jing1,*, Furong Huang1, Xukun Li1, Xiufeng Cao2, Zhihua Liu1

1The State Key Laboratory of Molecular Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Collaborative Innovation Center for Cancer Medicine, Beijing, China

2Department of Oncological Surgery, The Affiliated Nanjing 1st Hospital, Nanjing Medical University, Nanjing, China

*These authors have contributed equally to this work

Correspondence to:

Zhihua Liu, email: [email protected]

Keywords: integrin α6, esophageal cancer, metastasis, microRNA-92b

Received: May 04, 2016 Accepted: December 12, 2016 Published: December 27, 2016

ABSTRACT

Tumor invasion and metastasis is responsible for the poor prognosis of esophageal squamous cell carcinoma (ESCC); therefore, exploring the mechanisms by which malignant cells disseminate, spread and flourish in secondary sites, as well as translating the bench results to clinical practice are in urgent need. Previous reports showed that integrin α6 increases in ESCC specimens and its dysregulated spatial localization correlates positively with the unfavorable outcome of ESCC patients. Here, we clarify that integrin α6 promotes invasion and metastasis of ESCC cells In vitro and in vivo. Mechanistically, decreased integrin α6 attenuates motility of malignant cells partially through deactivating Akt pathway, which is essential for ESCC cells motility. Moreover, integrin α6 serves as a genuine target of miR-92b in suppressing ESCC motility. Our results for the first time describe that miR-92b/integrin α6/Akt axis controls the motility of ESCC, thereby providing a promising diagnosis or therapeutic option.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 14259

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

Integrin α6 promotes esophageal cancer metastasis and is targeted by miR-92b

Abstract